Compare Sana Biotechnology Inc (SANA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wheaton Precious Metals Corp — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Wheaton Precious Metals Corp trades at $138.54 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 73.1× Sana Biotechnology Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Wheaton Precious Metals Corp for 66 Days on average.
| SANA | WPM | |
|---|---|---|
Market Cap | $836.71M | $61.17B |
Volume | 4,507,444 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $165.72 |
52-Week Low | $2.68 | $94.37 |
Typical Hold Time | 23 Days | 66 Days |
Enterprise Value | $749.96M | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Wheaton Precious Metals (WPM) trades at $138.1, up 3.3% today, with a bearish technical signal despite recent earnings beats. The company reported record 2025 revenue of $2.31B and net income of $1.47B, supported by strong margins. Analyst consensus is bullish with an 80% buy rating and a $164.80 price target, while news highlights growth ambitions targeting 1.2M ounces by 2030.
WPM offers exposure to gold and silver streaming with robust profitability, but faces risks from gold price volatility and high valuations. The stock's upside hinges on execution of its funded growth pipeline, though technical indicators suggest near-term resistance near $138.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
